



Research Article

Susceptibility and Antimicrobial Resistance of Genital *Ureaplasma Parvum*

Ghofran Kadhim Al-khafaji✉

Technical Institute of Samawah, Al-Furat Al-Awsat University, Al-Samawah, Iraq.

✉ Corresponding author. E-mail: ghofran.alkhafaji1@gmail.com

Received: Aug. 1, 2017; **Accepted:** Sep. 7, 2017; **Published:** Sep. 27, 2017.**Citation:** Ghofran K. Al-khafaji, Susceptibility and Antimicrobial Resistance of Genital *Ureaplasma Parvum*. *Nano Biomed. Eng.*, 2017, 9(3): 236-241.**DOI:** 10.5101/nbe.v9i3.p236-241.

Abstract

The object of this study concentrated on investigating the antimicrobial susceptibilities of *Ureaplasma parvum* isolates to determine the most suitable antibiotic for treating the infection. In total, 35 samples of *Ureaplasma parvum* isolates were included in this study. Antibiotic susceptibility was studied by broth dilution method which was for the purpose of susceptibility testing of serovar isolates of *Ureaplasma parvum* against eight antibiotics. The results revealed the serovar 3 isolates were fully resistant (100%) to gentamicin, azithromycin and erythromycin while susceptible at the rates of 80% to doxycycline, 60% to levofloxacin and 60% to clarithromycin. Serovar 14 isolate was revealed fully susceptible (100%) to clarithromycin, ciprofloxacin and doxycycline, while fully resistant (100%) to gentamicin and azithromycin. Serovar 1 and serovar 6 were showed to be fully resistant (100%) to azithromycin and gentamicin. Serovar 1 was susceptible to at the rates of 70% to doxycycline, 60% to tetracycline, 90% to ciprofloxacin, 70% to levofloxacin, 70% to erythromycin and 70% to clarithromycin. Serovar 6 was susceptible at the rates of 80% to doxycycline, 100% to tetracycline, 100% to ciprofloxacin, 80% to levofloxacin, 80% to erythromycin and 80% to clarithromycin. These results evidently demonstrated that doxycycline, clarithromycin and levofloxacin should be the preferred drug when empirical treatment was required.

Keywords: Serovar; Susceptibility; Resistance; Suitable antibiotics; Isolates; *Ureaplasma parvum*; Empirical treatment; Antimicrobial; Broth dilution method; Mutation

Introduction

The administration of antimicrobial agents to pregnant women with preterm rupture of the membranes (PROM) may extend the gestation period and decrease the risk of associated complications and neonatal infections. The antimicrobial agent of choice should be considered carefully, as some agents are teratogens - i.e. the agent can cause malformation or functional damage to an embryo or fetus or may have toxic effects on the neonate [1]. Macrolides are often used empirically because of tetracyclines (TETs) and

fluoroquinolones being contraindicated in pregnancy. However, the amniotic sac is not effectively penetrated by erythromycin (ERY) and *Ureaplasma parvum* (*U. parvum*) are not eradicated from the vagina or cervix by this agent. Newer macrolides (e.g. azithromycin (AZM) and clarithromycin (CLR)) allow better tolerability and the once daily dosing benefit can increase compliance. Treatment with AZM was equally successful, compared to ERY but with fewer side effects [2]. *Ureaplasma* species (*Ureaplasma* spp.) contains one or more integrase recombinase genes. Some serovars contain transposases or its remnants and some phage

related proteins. The tetM gene was identified as part of a Tn916 transposon, in serovar 9 (SV9) which has acquired TET resistance. A report covering the years 2000-2004 from several states in the USA showed that 45% of unique clinical isolates of *Ureaplasma* spp. contained tetM and were TET-resistant [3]. The possibility of exchange of DNA between *U. parvum* and other pathogen within urogenital tract may contribute to gene transfer, which may promote antibiotic resistance in such pathogens [4]. There is only limited information on resistance development of *U. parvum*. *U. parvum* is innately resistant to antibiotics which act on cell wall components (the beta lactams). *Ureaplasma* spp. have natural resistance to lincosamides (e.g. clindamycin) [5]. Other observed resistance to macrolides is associated with mutations in the 23S rRNA gene, while resistance to TET is associated with the presence of the moveable tet M transposon. The tet M gene encodes a protein which binds to ribosomes, and in the case of *Ureaplasma* spp., it has been demonstrated to be associated, on the chromosome, with Tn916, a conjugative transposon [6]. Previous studies suggested that *Ureaplasma* spp. resistance to quinolone was mainly due to the mutants of target enzyme-DNA helicase; the residues 68-107 areas were the quinolone-resistant areas (quinolones regions of drug-resistance, QRDR) [7]. Besides beta lactams, *U. parvum* also shows resistance to sulphonamides, trimethoprim and rifampicin. Resistance to rifampicin is attributed to the presence of a single amino acid at position 526 of the beta sub unit of RNA polymerase. In a recent study conducted by Dhawan et al. [5] involving patients with infertility and genital discharge, all isolates of *U. parvum* isolates were susceptible to DOX and josamycin; 77% of the isolates were susceptible to ofloxacin and 71% to AZM. Though most studies reported lower resistance rates for TET (< 5%), a recent study by Redelinghuys et al. [2] demonstrated only 27% susceptibility of *U. parvum* isolates to TET. In a study by Zhu et al. [8] in Shanghai, biovar 1 (*Ureaplasma urealyticum*) showed high sensitivity rates (above 90%) to all antimicrobial agents; but biovar 2 (*U. parvum*) maintained higher sensitivities (above 95%) only to DOX and minocycline. In fact, only a small number of biovar 2 strains were sensitive to roxithromycin and quinolones. And *U. parvum* was shown to be resistant to TET and DOX, because the streptococcal tetM gene transposon was carrying TET-resistant genes (tetM) [20]. All strains of *U. parvum* were susceptible to josamycin and miocamycin and resistant to trimethoprim,

sulfonamides and rifampicin because they did not synthesize folic acid [20]. *U. parvum* had higher mutation rate than conventional bacteria which meant it could rapidly develop resistance to drugs including quinolone, ERY and AZM. Resistance developed in *U. parvum* by point mutation in parC (Pro-57 Leu), and two novel mutations in parE (Ile-73Thr and a methionine insertion at codon 86) were found in an ofloxacin-resistant strain [9, 10, 15].

Experimental

Antimicrobial agents

Antimicrobial susceptibility testing was performed against eight antimicrobial agents that included fluoroquinolones, macrolides, TETs and aminoglycosides, as shown in Table 1 [2, 10]. Each antimicrobial agent was prepared according to the manufacturers' instructions at a stock concentration of 250 mg/5 mL.

Table 1 Antibiotics used in antibiotic susceptibility testing

Antibiotics	Concentration (mg)	Company/origin
Ciprofloxacin	250	Ajanta/India
Levofloxacin	250	Ajanta/India
Azithromycin	250	Kontam/China
Erythromycin	250	Ajanta/India
Clarithromycin	250	Ajanta/India
Doxycycline	100	Ajanta/India
Tetracycline	250	Ajanta/India
Gentamicin	120	Menarini/Italy

Antibiotic susceptibility testing

Antibiotics susceptibility was determined by the standard broth dilution method by using Ibtisam habeeb (IH) broth medium containing serial dilution of antibiotics and antibiotics. The control broths were inoculated with bacterial suspension inoculation in IH broth medium [6]. The inoculated tube was incubated 2 days aerobically at 37 °C, then spread on IH agar medium and incubated anaerobically at 37 °C, and read after 24 h under compound light microscope (Olympus Japan) at 10× magnification. The Minimum inhibitory concentration (MIC) was defined as the lowest antibiotics concentration which inhibited the visible growth of *U. parvum* on the agar plate; the tentative breakpoints used were susceptible (S) and resistant (R).

Procedure of antimicrobial susceptibility testing by broth dilution method

A fixed amount of bacteria was cultured in IH broth

medium in sterile test tubes. The concentrations were numbered for the addition of antibiotic [9].

Antibiotics were added to make the concentrations in an ascending order, so that the first tube (No.1) contained a zero concentration of antibiotics (control), followed by the second tube (No. 2) that had lower concentration of the antibiotic, and followed by the third tube (No. 3) which contained double the concentration in the tube No. 2 [10].

All the tubes were incubated at the optimum temperature of 37 °C, then the incubation was investigated, and the growth of bacteria was identified in terms of turbidity. The clear tubes indicated lack of growth of the bacteria as a result of the effectiveness of antibiotics. As in this study *U. parvum* during its growth did not appear any turbidity in broth, it was kept in the IH agar medium and incubated anaerobically at 37 °C for 24 h. Then the plates were investigated to identify the growth of bacteria in terms of colonies. The clear plates indicated lack of growth of the bacteria as a result of the effectiveness of antibiotics.

Calculation: To prepare the concentration gradient of the antibiotics 0, 4, 8, 16, 32, 64, 128, 256... µg/mL, 250 mg of ciprofloxacin (CIP) was dissolved in 5 mL distilled water (DW) thus making a concentration of 250 mg/5 mL, i.e. 50 mg/1 mL. The units were turned into microgram: $50 \times 1,000 = 50,000 \mu\text{g/mL} = \text{Stock 1}$. Stock 2 = 200 µg / 100 mL was prepared from stock 1.

$$C1V1 = C2V2 \quad 50,000 \times V1 = 200 \times 100 \quad V1 = 0.4$$

0.4 mL from Stock 1 + 99.6 D.W became Stock 2 = 200 µg / 100 mL. All the concentrations were prepared as required and with the final volume of 2 mL.

$0 = C1V1 = C2V2 = 0$	Controls
$4 = 200 \times V1 = 4 \times 2$	$V1 = 0.04 \text{ mL}$
$8 = 200 \times V1 = 8 \times 2$	$V1 = 0.08 \text{ mL}$
$16 = 200 \times V1 = 16 \times 2$	$V1 = 0.16 \text{ mL}$
$32 = 200 \times V1 = 32 \times 2$	$V1 = 0.32 \text{ mL}$
$64 = 200 \times V1 = 64 \times 2$	$V1 = 0.64 \text{ mL}$
$128 = 200 \times V1 = 128 \times 2$	$V1 = 1.28 \text{ mL}$
$256 = 200 \times V1 = 256 \times 2$	$V1 = 2.56 \text{ mL}$

Results and Discussion

Many reports have suggested that *U. parvum*

may be associated with urogenital infections, infertility and adverse pregnancy outcomes [11]. According to previous studies, eight antibiotic agents including DOX, AZM, gentamicin (GEN), CIP, TET, levofloxacin (LVX), ERY and CLR were tested on 35 samples of *U. parvum*, as they are the major antibiotics used in the treatment of genital tract infection caused by *U. parvum*. A further purpose of choosing these antimicrobial agents was they are conventionally being used for the routine treatment of sexually transmitted infections [6, 9, 10, 12]. In addition, a new macrolide CLR was also tested. The results are revealed in Table 2, showing that *U. parvum* isolates were 80% susceptible to DOX (MIC: 8 µg/mL), 71.4% to CLR (MIC: 8 µg/mL), 60% to TET (MIC: 8 µg/mL), 42.8% to ERY (MIC: 16 µg/mL), 65.7% to LVX (MIC: 4 µg/mL) and 74.2% to CIP (MIC: 256 µg/mL).

Table 2 Antibiotics used in antibiotic susceptibility testing

Antibiotics/total number (35)	MIC (µg/mL)	Rate susceptibility
Ciprofloxacin	256	26 (74.2%)
Levofloxacin	4	23 (65.7%)
Azithromycin	-	0
Erythromycin	16	15 (42.8%)
Clarithromycin	8	25 (71.4%)
Doxycycline	8	28 (80%)
Tetracycline	8	21 (60%)
Gentamicin	-	0

Also, the results showed that *U. parvum* isolates were 91% susceptible to DOX (16 µg/mL), 85.7% to CLR (16 µg/mL), 65.7% to TET (16 µg/mL), 54.2% to ERY (32 µg/mL) and 82.8% to LVX (8 µg/mL). The *U. parvum* isolates were highly resistant (100%) to CIP (4-128 µg/mL), AZM (4-256 µg/mL) and GEN (4-256 µg/mL) as recorded in this investigation (Fig. 1). The results of the present study were similar to those of other studies on the rates of susceptibility of *U. parvum* to antibiotics [5, 9, 12].

U. parvum has been considered susceptible to macrolides; however, in the present study, *U. parvum* was resistant to AZM and ERY. Similar to the findings of Kilic et al. [7], AZM's resistance to strains of *U. parvum* was reported with increasing frequency. The resistance against AZM developed in *U. parvum* by a point mutation in parC, and two novel mutations in parE were found in an ofloxacin-resistant strain [11,13]. That the strains of *U. parvum* were resistant to ERY [12] may be because of the mutations in the L22 ribosomal protein which were seen in three strains that were




Fig. 1 Susceptibility results of *U. parvum* to different antibiotics.

resistant to ERY [4]. No resistance was seen against the new macrolide CLR in *U. parvum*, and the results were similar to those reported earlier [10, 14].

TET and DOX were the most active agents against *U. parvum*. This finding was consistent with those of other studies conducted in China [4, 15] and Turkey [7, 16]. The majority of *U. parvum* serovars were susceptible to DOX, CLR and LVX, while *U. parvum* serovars were fully resistant (100%) to GEN and AZM [13]. The resistance to GEN and AZM was of intermediate nature in all the *U. parvum* isolates. The results revealed that SV3 isolates were fully resistant (100%) to GEN, AZM and ERY, while susceptible to DOX in the rates of 80% and 60% to LVX and 60% to CLR. SV14 isolates were revealed to be fully susceptible (100%) to CLR, CIP and DOX, while fully resistant (100%) to GEN and AZM. SV1 and SV6 showed full resistance (100%) to AZM and GEN. SV1 was susceptible in the rates of 70% to DOX, 60% to TET, 90% to CIP, 70% to LVX, 70% to ERY and 70% to CLR, while SV6 was susceptible at the rates of 80% to DOX, 100% to TET, 100% to CIP, 80% to LVX, 80% to ERY and 80% to CLR. The results were shown in Fig. 2.

The study further observed that *U. parvum* SV3 was the most frequent serovar detected in patients and was susceptible to DOX, LVX and CLR [14] while resistant to ERY, AZM and GEN. This finding was consistent with those of other studies [6, 7, 17].

The fluoroquinolones are considered useful in the treatment of Ureaplasma infections as they are potentially effective against pathogenic species and

contain strains that are resistant to other drugs such as DOX. Fluoroquinolones are used for treating urogenital infections; they interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the *gyrA* and *gyrB* genes for DNA gyrase and *parC* and *parE* genes for topoisomerase IV [9].

The results in the present study showed that *U. parvum* isolate was susceptible to levofloxacin. However, *U. parvum* was resistant to CIP (fluoroquinolones). Similar rates of resistance to quinolones were observed in clinical isolates of *U. parvum* in most of the studies [7, 16, 18]. There were some reports of fluoroquinolone-resistant *U. parvum* in the field of urology in Japan [11]. Resistance against fluoroquinolones in *U. parvum* may occur to some degree due to the widespread use of these drugs for the treatment of respiratory and urogenital infections. *U. parvum* resistance to fluoroquinolones has been attributed to substitution mutations, principally in *gyrA* and *parC* genes, and to a lesser extent in *gyrB* and *parE* genes of the DNA gyrase / topoisomerase IV complex [17]. Six mutations in *parC* gene, five mutations in *parE* and one mutation in *gyrA* which resulted in amino acid substitutions were identified in *U. parvum*. There were only three silent mutations observed in *gyrB*. The *gyrA* mutation that resulted in the substitution of glutamine for lysine at amino acid 103 in *U. parvum* may be near enough to the tyrosine active site of the protein at amino acid 122 to contribute to the resistance against CIP as observed [6, 7].




Fig. 2 Susceptibility (MIC) of serovars to different antibiotics.

However, a high rate of resistance to GEN was observed for *U. parvum*. GEN belongs to the group of aminoglycosides which are not active against anaerobes bacteria. Three mechanisms of resistance have been recognized, namely ribosome alteration, decreased permeability and inactivation of the drugs by aminoglycoside modifying enzymes. The latter mechanism is of most clinical importance since the genes encoding aminoglycoside modifying enzymes can be disseminated by plasmids or transposons [2, 6, 19]. Ribosome alteration can result in single mutations in chromosomal genes encoding ribosomal proteins: rpsL (or strA), rpsD (or ramA or sud) and rpsE (eps or spc or spcA) [15]. Decreased permeability alteration in the aminoglycoside transport system, inadequate membrane potential and modification in the LPS (lipopolysaccharides) phenotype can result in a cross resistance to all aminoglycosides. In the activation of aminoglycosides, these enzymes are classified into three major classes according to the type modification: acetyltransferases (AAC), nucleotidyltransferases or adenytransferases (ANT) and phosphotransferases (APH) [7].

Conclusions

These results evidently indicated that DOX, CLR and LVX should be the drug of first choice when empirical treatment is required. The results revealed in the present study indicated that *U. parvum* colonizing the genital tract epithelium might come from biofilms that protected organisms from host defenses and

antibiotic treatment. To confirm the biologic relevance of the current *in-vitro* studies, biofilm-formation of clinical *U. parvum* isolates should be tested with *in-vivo* experimental models. Treatment of *U. parvum* infection is imperative to prevent the occurrence of complications. Empirical therapy is important in the treatment of *U. parvum* infections.

Conflict of Interests

The authors declare that no competing interest exists.

References

- [1] F. Santos, O. Sheehy, S. Perreault, et al., Trends in anti-infective drugs use during pregnancy. *Journal of Popul Ther Clin Pharmacol*, 2012, 19: 460-465.
- [2] M.J. Redelinghuys, M.M. Ehlers, A.W. Dreyer, et al., Comparison of the new Mycofast Revolution assay with a molecular assay for the detection of genital mycoplasmas from clinical specimens. *South Africa Journal of BMC Infect Dis*, 2013, 9: 453-455.
- [3] K.B. Waites, B. Katz, and R.L. Schelonka, Mycoplasmas and Ureaplasma as neonatal pathogens. *Clin Microbiol Rev*, 2005, 18: 757-789.
- [4] S. Govender, L.J. Chalkley, Tetracycline resistance genes of Ureaplasmas. *South Afr. Journal of Epidemiol Infect*, 2012, 27: 19-23.
- [5] B. Dhawan, N. Malhotra, V. Sreenivas, et al., Ureaplasma serovars & their antimicrobial susceptibility in patients of infertility & genital tract infections. *Indian Journal of Medicine Research*, 2012, 12: 991-996.
- [6] M.L. Beeton, V.J. Chalker, L.C. Jones, et al., Antibiotic resistance among clinical Ureaplasma isolates recovered from neonates in England and Wales. *Antimicrob Agents Chemother*, 2016, 1: 52-56.

- [7] L. Xiao, D.M. Crabb, L.B. Duffy, et al., Chromosomal mutations responsible for fluoroquinolone resistance in *Ureaplasma* spp. in the United States. *Antimicrobial agents and chemotherapy*, 2012, 56: 2780-2783.
- [8] C.T. Zhu, Z.Y. Hu, C.L. Dong, et al., Investigation of *Ureaplasma urealyticum* biovars and their relationship with antimicrobial resistance. *Indian J Med Microbiol*, 2011, 29: 288-292.
- [9] Y. Kawai, Y. Nakura, T. Wakimoto, et al., In vitro activity of five quinolones and analysis of the quinolone resistance determining region of *gyrA*, *gyrB*, *parC*, and *parE* in *Ureaplasma parvum* and *Ureaplasma urealyticum* clinical isolates from perinatal patients in Japan. *Antimicrob Agents Chemother*, 2015, 14: 1-12.
- [10] Y. Miura, M.S. Payne, J.A. Keelan, et al., Maternal intravenous treatment with either azithromycin or solithromycin clears *Ureaplasma parvum* from the amniotic fluid in an ovine model of intrauterine infection. *Antimicrobial Agents and Chemotherapy*, 2014, 9: 5413-5420.
- [11] Y. Kamiya, Y. Shimada, S. Ito, et al., Analysis of the quinolone-resistance determining region of the *gyrA* gene and the analogous region of the *parC* gene in *Ureaplasma parvum* and *Ureaplasma urealyticum* detected in first-void 356 urine of men with non-gonococcal urethritis. *Journal of Antimicrobial Chemotherapy*, 2013, 68: 480-482.
- [12] R. Krausse, S. Schubert, In vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against *Mycoplasma hominis* and *Ureaplasma* spp. isolated in Germany over 20 years. *Clin Microbiol Infect*, 2010, 16: 1649-1655.
- [13] R.M. Bayraktar, H.I. Ozerol, N. Gucluer, et al., Prevalence and antibiotic susceptibility of *Mycoplasma hominis* and *Ureaplasma urealyticum* in pregnant women. *Int J Infect Dis*, 2010, 14: 90-95.
- [14] K.A. Stellrecht, M.A. Woron, G.N. Mishrik, et al., Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas. *Journal of Clin Microbiol*, 2010, 42: 1528-1533.
- [15] H.P. Lin, H.X. Lu, Analysis of detection and antimicrobial resistance of pathogens in prostatic secretion from 1186 infertile men with chronic prostatitis. *Journal of Zhonghua Nan Ke Xue*, 2007, 13: 628-631.
- [16] D. Kilibic, M.M. Basar, S. Kaygusuz, et al., Prevalence and treatment of *Chlamydia trachomatis*, *Ureaplasma urealyticum* and *Mycoplasma hominis* in patients with non-gonococcal urethritis. *Journal of Infect Dis*, 2004, 57: 17-20.
- [17] M.S. Ramirez, M.E. Tolmasky, Aminoglycoside modifying enzymes. *Journal of Drug resistance update*, 2010, 6: 151-171.
- [18] F.Santos, O. Sheehy, S. Perreault, et al., Trends in anti-infective drugs use during pregnancy. *Journal of Popul Ther Clin Pharmacol*, 2012, 19: 460-465.
- [19] R. Romero, L. Yeo, J. Miranda, et al., Ablueprint for the prevention of preterm birth vaginal progesterone in women with a short cervix. *Journal of Perinat Med*, 2013, 1: 27-44.
- [20] B.B. Mardassi, N. Aissani, I. Moalla, et al., Evidence for the predominance of a single tet(M) gene sequence type in tetracycline-resistant *Ureaplasma parvum* and *Mycoplasma hominis* isolates from Tunisian patients. *Journal of Med Microbial*, 2012, 9:1254-1261.

Copyright© 2017 Ghofran Kadhim Al-khafaji. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.